Medpace Holdings, Inc. $MEDP Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company raised its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 38.9% during the 2nd quarter, Holdings Channel reports. The fund owned 20,043 shares of the company’s stock after purchasing an additional 5,610 shares during the period. The Manufacturers Life Insurance Company’s holdings in Medpace were worth $10,615,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently modified their holdings of the business. California State Teachers Retirement System increased its holdings in shares of Medpace by 53,619.6% during the second quarter. California State Teachers Retirement System now owns 13,989,649 shares of the company’s stock valued at $7,408,778,000 after purchasing an additional 13,963,607 shares during the period. BlackRock Inc. acquired a new stake in Medpace in the second quarter worth about $1,323,047,000. AQR Capital Management LLC lifted its holdings in Medpace by 31.6% in the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock worth $758,061,000 after purchasing an additional 324,293 shares during the period. Wasatch Advisors LP grew its position in Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after buying an additional 116,354 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Medpace by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after buying an additional 24,625 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 0.7%

Shares of NASDAQ MEDP opened at $587.52 on Friday. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The company has a market capitalization of $16.40 billion, a price-to-earnings ratio of 34.44, a PEG ratio of 2.62 and a beta of 1.15. The firm has a 50-day moving average of $579.00 and a two-hundred day moving average of $504.67.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter last year, the firm posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have commented on MEDP. Mizuho boosted their price target on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $535.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and boosted their target price for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Finally, Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. Three investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $595.20.

Insider Buying and Selling at Medpace

In related news, CEO August Troendle sold 650 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $620.27, for a total transaction of $403,175.50. Following the completion of the sale, the chief executive officer directly owned 539,894 shares in the company, valued at approximately $334,880,051.38. This trade represents a 0.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Kevin Brady sold 3,400 shares of Medpace stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $625.24, for a total transaction of $2,125,816.00. Following the completion of the transaction, the chief financial officer owned 12,830 shares in the company, valued at approximately $8,021,829.20. This trade represents a 20.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 134,471 shares of company stock valued at $82,151,311 in the last ninety days. Company insiders own 20.50% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.